ALK and lung adenocarcinoma: We tested these hypotheses further by developing our own in vitro models of crizotinib resistance using human ALK+ lung adenocarcinoma cells, studying both the effects of IGF-1R inhibition shortly after crizotinib treatment and chronic crizotinib exposure.